Travere Therapeutics (TVTX) Restructuring Costs (2016 - 2024)
Travere Therapeutics (TVTX) reported Restructuring Costs of $1.4 million for Q4 2024, down 88.02% on a YoY basis from $11.4 million in Q1 2024, and up 1009.76% quarter-over-quarter from $123000.0 in Q3 2024.
Travere Therapeutics (TVTX) Restructuring Costs (2016 - 2024) Analysis & Trends
Travere Therapeutics has reported Restructuring Costs for 4 years, with the latest figure at $1.4 million in Q4 2024.
- For the quarter ending Q4 2024, Restructuring Costs fell 88.02% year-over-year to $1.4 million; the trailing twelve-month figure through Sep 2025 stood at $1.4 million (down 89.02% YoY), and the FY2024 full-year result was $2.4 million, down 78.94% from the prior year.
- Restructuring Costs for Q4 2024 stood at $1.4 million, up from $123000.0 in the prior quarter.
- The five-year high for Restructuring Costs was $11.4 million in Q4 2023, with the low at $123000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Travere Therapeutics | 5.07 Bn | 4.99 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 123,000.00 |
| Jun 30, 2024 | 653,000.00 |
| Mar 31, 2024 | 259,000.00 |
| Dec 31, 2023 | 11.39 Mn |
| Dec 31, 2017 | 1.61 Mn |
| Jun 30, 2017 | 981,000.00 |
| Mar 31, 2017 | 498,000.00 |
| Sep 30, 2016 | 5.21 Mn |